RLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2020
JANUARY 1[st] - MARCH 31[st] · Net sales amounted to TSEK 374 (260 TSEK) · The operating loss for the period was MSEK -3.9 (-5.7 MSEK) · Earnings per share after dilution at SEK -0.06 (-0.04) · Cash flow from operating activities amounted to MSEK -4.2 (-5.5 MSEK) · Equity ratio was 92 percent (84 percent)NOTABLE EVENTS DURING THE PERIOD · A success for the clinical trial ChloraSolv01 where we have included all patients · Revisions of Lloyd’s regarding our quality assurance system and of Eurofins, which is our new Notified Body for directives of medical devices. The